Novo Nordisk’s NVO shares misplaced 5.3% on Friday after Medicare issued a press launch choosing the corporate’s fashionable semaglutide medicines as one of many 15 extra medicine coated below Medicare Half D for the second spherical of worth negotiations in 2025. Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for kind II diabetes (T2D) and Wegovy injections for weight administration.
Any worth discount ensuing from the upcoming negotiations will turn out to be efficient in 2027. For continued protection of its semaglutide medicines below Medicare, NVO has till Feb. 28, 2025, to resolve if it’ll take part in negotiations or pay a big tax on U.S. gross sales of the medicine. Both means, buyers anticipate a decline within the firm’s revenue margins ensuing within the inventory worth decline. The Inflation Discount Act permits Medicare to barter the costs of sure pharmaceuticals to make them extra reasonably priced for seniors and other people with disabilities.
Medicare acknowledged that, from November 2023 to October 2024, roughly 5.3 million Medicare Half D beneficiaries used these 15 chosen medicine to deal with situations like most cancers, T2D and bronchial asthma. Throughout the identical interval, these medicine accounted for round $41 billion, or 14%, of the overall gross coated prescription drug prices below Medicare Half D.
Up to now three months, Novo Nordisk’s shares have plunged 32.9% in contrast with the industry’s 16.6% decline.
Picture Supply: Zacks Funding Analysis
Please notice that shares of NVO’s archrival within the weight problems house, Eli Lilly LLY, additionally declined 4.2% on Friday, though none of its medicine had been chosen for the second spherical of worth negotiations. Eli Lilly markets its tirzepatide medicines, Mounjaro for T2D and Zepbound for weight problems, which competes with NVO’s Ozempic and Wegovy. The autumn in LLY’s inventory worth is probably going as a result of buyers additionally anticipate the number of its tirzepatide medicines by Medicare for worth negotiations sooner or later.
In 2023, Medicare chosen 10 medicine for its first spherical of worth negotiations. Agreements had been reached with drug producers to ascertain new, decreased costs for all 10 medicine. These costs, reflecting reductions of 38% to 79% off checklist costs, will take impact on Jan. 1, 2026.
NVO’s Increased Dose Semaglutide Outshines Wegovy in Weight problems Examine
In its newest press launch, Novo Nordisk introduced topline information from a late-stage examine evaluating the efficacy and security of as soon as weekly, subcutaneous semaglutide 7.2 mg in contrast with Wegovy and placebo in adults with weight problems.
Per the information readout, the part IIIb STEP UP examine met its major endpoint by demonstrating a statistically vital and superior weight reduction at week 72 with semaglutide 7.2 mg versus placebo.
Evaluation of the information, assuming all individuals adhered to therapy, revealed that sufferers beginning with a imply baseline weight of 113 kg skilled a superior weight lack of 20.7% after 72 weeks with semaglutide 7.2 mg, in comparison with 17.5% with Wegovy and a pair of.4% with placebo. Moreover, 33.2% of these on semaglutide 7.2 mg achieved no less than a 25% weight reduction after 72 weeks, in comparison with 16.7% on Wegovy and none on placebo.
No matter therapy adherence, it was noticed that individuals handled with semaglutide 7.2 mg achieved a superior weight lack of 18.7% in comparison with a discount of 15.6% with Wegovy and three.9% with placebo. Moreover, the candidate demonstrated a protected and well-tolerated profile. Antagonistic occasions associated to therapy had been largely delicate to reasonable in severity and diminished over time, per the GLP-1 receptor agonist class.
Novo Nordisk expects to share detailed outcomes from the part IIIb STEP UP examine of semaglutide 7.2 mg for weight problems at a medical convention later in 2025. The corporate additionally expects to share outcomes from the second part III examine, STEP UP T2D, of semaglutide 7.2 mg for adults with T2D and weight problems, within the subsequent few months.
Novo Nordisk A/S Value and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
NVO’s Zacks Rank & Shares to Think about
Novo Nordisk at the moment carries a Zacks Rank #4 (Promote).
Some better-ranked shares from the sector are Citadel Biosciences CSTL and BioMarin Pharmaceutical BMRN, every sporting a Zacks Rank #1 (Sturdy Purchase) at current. You’ll be able to see the complete list of today’s Zacks #1 Rank stocks here.
Up to now 30 days, Citadel Biosciences’ earnings estimates for 2024 have remained fixed at 34 cents per share. Throughout the identical timeframe, loss per share for 2025 has remained fixed at $1.84. Up to now three months, shares of Citadel Biosciences have plunged 21.7%.
CSTL’s earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 172.72%.
Up to now 30 days, estimates for BioMarin Pharmaceutical’s 2024 earnings per share have improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 throughout the identical timeframe. Up to now three months, BioMarin Pharmaceutical shares have misplaced 12.5%.
BMRN’s earnings beat estimates in every of the trailing 4 quarters, delivering a mean shock of 28.7%.
5 Shares Set to Double
Every was handpicked by a Zacks knowledgeable because the #1 favourite inventory to achieve +100% or extra in 2024. Whereas not all picks may be winners, earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
Many of the shares on this report are flying below Wall Avenue radar, which supplies an ideal alternative to get in on the bottom ground.
Today, See These 5 Potential Home Runs >>
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
